<DOC>
	<DOCNO>NCT00033332</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Thalidomide may stop growth cancer stop blood flow tumor . Combining dexamethasone thalidomide may kill cancer cell . It yet know whether dexamethasone effective without thalidomide treat multiple myeloma . PURPOSE : Randomized phase III trial determine effectiveness dexamethasone without thalidomide treat patient multiple myeloma .</brief_summary>
	<brief_title>Dexamethasone With Without Thalidomide Treating Patients With Newly Diagnosed Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : - Compare response rate patient newly diagnose multiple myeloma treat dexamethasone without thalidomide . - Compare toxicity regimens patient . - Assess effect thalidomide bone marrow microvessel density angiogenesis grade expression vascular endothelial growth factor basic fibroblast growth factor patient . OUTLINE : This randomize , multicenter study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral thalidomide daily day 1-28 oral dexamethasone daily day 1-4 , 9-12 , 17-20 . Patients also receive either pamidronate IV 2-4 hour zoledronate IV 15 minute day 1 bone strengthening . - Arm II : Patients receive dexamethasone pamidronate zoledronate arm I . Treatment arm repeat every 28 day 4 course absence disease progression unacceptable toxicity . Patients may receive additional course fourth course physician 's discretion . Patients follow every 3 month 2 year , every 6 month 3 year , annually 2 year . PROJECTED ACCRUAL : A total 194 patient ( 97 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Pamidronate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose symptomatic multiple myeloma confirm follow : Bone marrow plasmacytosis least 10 % plasma cell sheet plasma cell biopsyproven plasmacytosis Monoclonal protein ( M protein ) least 1.0 g/dL serum protein electrophoresis least 200 mg monoclonal light chain 24hour urine protein electrophoresis No smolder myeloma monoclonal gammopathy undetermined significance PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count great 1,000/mm^3 Platelet count great 50,000/mm^3 Hemoglobin great 7 g/dL Hepatic : Bilirubin great 1.5 mg/dL ALT AST great 2.5 time upper limit normal Renal : Creatinine le 3 mg/dL Cardiovascular : No prior concurrent deep venous thrombosis Other : Prior malignancy allow provide follow criterion meet : Received prior treatment curative intent Free disease time period appropriate cure specific cancer No grade 2 great peripheral neuropathy due medical condition No active infection Not pregnant nursing Negative pregnancy test Fertile patient must use 1 highly effective method 1 additional method contraception 1 month , , 4 week study woman effective barrier contraception men 4 week study participation PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic therapy multiple myeloma No concurrent biologic therapy multiple myeloma Chemotherapy : No prior chemotherapy multiple myeloma No concurrent chemotherapy multiple myeloma Endocrine therapy : More 6 month since prior systemic dexamethasone glucocorticoids No concurrent corticosteroid Radiotherapy : At least 4 week since prior palliative , localized radiotherapy Concurrent palliative , localize radiotherapy allow physician 's discretion Surgery : Not specify Other : No prior systemic therapy multiple myeloma , except bisphosphonates No concurrent anticoagulant therapy deep vein thrombosis No concurrent barbiturates alcohol ( thalidomide arm )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2005</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>